Announcement
10.02.2012
NeuroSearch A/S (NEUR) has decided to conduct the Annual General Meeting on
Tuesday, 10 April 2012
This changes the previously announced date which was 25 April 2012.
Submission of motions Shareholders who wish to submit motions for the Annual General Meeting must do so in writing to the Board of Director no later than Tuesday, 28 February 2012. Please submit either electronically to investor@neurosearch.com or by ordinary mail to the company's postal address. Please mark 'Annual General Meeting'.
Patrik Dahlen CEO
Contact person: René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS) disorders. The vision is to develop NeuroSearch into a profitable specialty pharmaceutical company. The strategy is to complete the development and subsequently to market Huntexil®, a unique drug in clinical Phase III for the treatment of the motor symptoms of Huntington's disease. As a consequence of the restructuring of NeuroSearch that was announced 27 September 2011, the company also has a portfolio of assets for outlicensing or divestment.
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=377862
NeuroSearch A/S (NEUR) has decided to conduct the Annual General Meeting on
Tuesday, 10 April 2012
This changes the previously announced date which was 25 April 2012.
Submission of motions Shareholders who wish to submit motions for the Annual General Meeting must do so in writing to the Board of Director no later than Tuesday, 28 February 2012. Please submit either electronically to investor@neurosearch.com or by ordinary mail to the company's postal address. Please mark 'Annual General Meeting'.
Patrik Dahlen CEO
Contact person: René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS) disorders. The vision is to develop NeuroSearch into a profitable specialty pharmaceutical company. The strategy is to complete the development and subsequently to market Huntexil®, a unique drug in clinical Phase III for the treatment of the motor symptoms of Huntington's disease. As a consequence of the restructuring of NeuroSearch that was announced 27 September 2011, the company also has a portfolio of assets for outlicensing or divestment.
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=377862
